ReviewExpert review of hematology2013
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Review in Expert review of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.Clinical and experimental medicine · 2020Pooled it
- Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.European journal of medical research · 2025Article
- Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes.Annals of hematology · 2024Article
- Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.JCO global oncology · 2024Article
- Iron overload during the treatment of acute leukemia: pretransplant transfusion experience.International journal of hematologic oncology · 2021Article
- Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.Cancers · 2021Review
- Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.Annals of hematology · 2021Article
- Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.Cancer treatment and research · 2021Review
- Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options.Cancer management and research · 2021Review
- High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.Technology in cancer research & treatment · 2018Article
- Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.Health and quality of life outcomes · 2017Observational
- Should every Patient with MDS get Iron Chelation - Probably Yes.Mediterranean journal of hematology and infectious diseases · 2017Article
- Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.Journal of comparative effectiveness research · 2015Article
- Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.Journal of blood medicine · 2015Review
- Desferrithiocin: a search for clinically effective iron chelators.Journal of medicinal chemistry · 2014Review
- There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Current hematologic malignancy reports · 2013Review
- Current therapy of myelodysplastic syndromes.Blood reviews · 2013Review
- Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes.South Asian journal of cancerReview
- Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Anemia leading to transfusion dependency (TD) and iron overload (IO) is commonly observed in patients with myelodysplastic syndromes (MDS). In MDS, TD and IO have been retrospectively associated with inferior survival and worse clinical outcomes, including cardiac, hepatic and endocrine dysfunction, and, in some analyses, with leukemic progression and infectious complications. Although suggested by retrospective analyses, clear prospective documentation of the beneficial effects of iron chelation therapy (ICT) on organ function and survival in MDS patients with TD and IO is currently lacking. Consequently, the role of ICT in MDS patients with TD and IO remains a very controversial aspect in the management of MDS. In this review, the authors summarize the current knowledge regarding IO in MDS and the role of ICT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.